Pfizer forecasts earnings from the COVID-19 vaccine it developed with BioNTech will now reach $36 billion this 12 months, up 7.5% from its old estimate of $33.5 billion.
Why it matters: This vaccine has quickly develop into the maximum-selling drug on this planet, but public health experts and world leaders remain concerned concerning the vaccine's uneven distribution which has left poorer nations with far fewer doses to administer.
dwell on accurate of the newest market trends and economic insights with Axios Markets. Subscribe for gratis
by the numbers: Pfizer registered $13 billion of precise COVID-19 earnings in the third quarter, bringing year-to-date 2021 income to $24.three billion.
Pfizer mentioned its income margin on the vaccine, earlier than taxes and after splitting income with BioNTech, is the "excessive 20s," which means vaccine profits may method $10 billion just for Pfizer this yr.
Pf izer expects the vaccine will generate an further $29 billion of earnings in 2022, and that's the reason based mostly best on 1.7 billion doses dedicated to purchasing contracts.
Pfizer observed it's going to manufacture as much as four billion doses next yr, that means there are 2.3 billion doses it might nevertheless sell.
The bottom line: The Pfizer-BioNTech vaccine is extremely valuable and has saved tens of millions of lives. or not it's also turn into of the greatest moneymakers in pharmaceutical background.
more from Axios: sign up to get the newest market developments with Axios Markets. Subscribe at no cost
0 Comments